Loading...
Technetium 99m bone scans remain the primary diagnostic imaging test to assess bone metastases in patients with advanced prostate cancer. However, use of the scans to differentiate true disease progression from pseudoprogression (a healing response) is challenging because both appear as new, unconfirmed lesions based on osteoblastic uptake.
To determine the association between such lesions and outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who are receiving treatment with enzalutamide, investigators conducted a retrospective analysis of 643 men from the PREVAIL study (NCT0121991) who had not received docetaxel and 404 men from the AFFIRM study (NCT00974311) who had received docetaxel. Eligible patients had …